Bio-Techne Corp
NASDAQ:TECH
Intrinsic Value
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. [ Read More ]
The intrinsic value of one TECH stock under the Base Case scenario is 49.78 USD. Compared to the current market price of 63.87 USD, Bio-Techne Corp is Overvalued by 22%.
Valuation Backtest
Bio-Techne Corp
Run backtest to discover the historical profit from buying and selling TECH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bio-Techne Corp
Current Assets | 590.6m |
Cash & Short-Term Investments | 135.7m |
Receivables | 207.5m |
Other Current Assets | 247.5m |
Non-Current Assets | 2.1B |
PP&E | 335.1m |
Intangibles | 1.5B |
Other Non-Current Assets | 274.4m |
Current Liabilities | 135.2m |
Accounts Payable | 31.5m |
Accrued Liabilities | 62.8m |
Other Current Liabilities | 40.9m |
Non-Current Liabilities | 632m |
Long-Term Debt | 447m |
Other Non-Current Liabilities | 185m |
Earnings Waterfall
Bio-Techne Corp
Revenue
|
1.1B
USD
|
Cost of Revenue
|
-376.2m
USD
|
Gross Profit
|
768.7m
USD
|
Operating Expenses
|
-490.1m
USD
|
Operating Income
|
278.6m
USD
|
Other Expenses
|
-54.4m
USD
|
Net Income
|
224.2m
USD
|
Free Cash Flow Analysis
Bio-Techne Corp
TECH Profitability Score
Profitability Due Diligence
Bio-Techne Corp's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Bio-Techne Corp's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
TECH Solvency Score
Solvency Due Diligence
Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TECH Price Targets Summary
Bio-Techne Corp
According to Wall Street analysts, the average 1-year price target for TECH is 82.43 USD with a low forecast of 65.65 USD and a high forecast of 99.75 USD.
Ownership
TECH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TECH Price
Bio-Techne Corp
Average Annual Return | 20.22% |
Standard Deviation of Annual Returns | 39.05% |
Max Drawdown | -60% |
Market Capitalization | 10B USD |
Shares Outstanding | 157 192 000 |
Percentage of Shares Shorted | 4.4% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 2,600 full-time employees. The firm operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.
Contact
IPO
Employees
Officers
The intrinsic value of one TECH stock under the Base Case scenario is 49.78 USD.
Compared to the current market price of 63.87 USD, Bio-Techne Corp is Overvalued by 22%.